全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Correlation between C-Peptide Level and Chronic Microvascular Complications in Type 2 Diabetes Mellitus Sudanese Patients

DOI: 10.4236/oalib.1102634, PP. 1-7

Subject Areas: Metabolic Sciences

Keywords: C-Peptide, Diabetic Complications, Nephropathy, Peripheral Neuropathy, Retinopathy

Full-Text   Cite this paper   Add to My Lib

Abstract

Background: C-peptide is a by-product of insulin biosynthesis released in the circulation in amount equimolar with that of insulin; therefore C-peptide has been used as an index of insulin secretion and its potential role as a predictor of pancreatic and colorectal cancer and kidney disease have been questioned. The relation between C-peptide and diabetic complications attracted the attention of many investigators but not well established yet. The aim of the present study was to explore the relationship between the level of C-peptide and the diabetic microvascular complications in Sudanese patients. Patients and Methods: One hundred and eighty-one type 2 diabetic patients, 61% males and 39% females, aged more than 30 years were recruited from different Khartoum hospitals and studied cross-sectionally. Levels of blood C-peptide and HbA1C were measured with commercially available ELISA kit, and the diabetic complications were determined subjectively by experienced physicians. Results: Patients with no complications showed the highest prevalence 33.7% followed by peripheral neuropathy 33.1%, retinopathy 21.2% and finally nephropathy 11%. Both no-complications (9.05 ± 3.288) and retinopathy (9.10 ± 3.34) groups showed similar level of C-peptide, P value = 0.939. While nephropathy group (5.50 ± 3.73) and peripheral neuropathy (6.60 ± 3.02) showed significantly low levels as compared to that of no complication, P value = 0.000. On the other hand, level of HbA1C showed difference between retinopathy and nephropathy when compared to no complication group but not the peripheral neuropathy. Conclusion: The results of the present study suggest that the most prevalent diabetic complication in Sudanese patients is peripheral neuropathy, and the association between C-peptide and diabetic complications is more prominent with nephropathy and peripheral neuropathy rather than retinopathy.

Cite this paper

Adam, K. M. , Tajelsir, S. and Aowad, D. A. (2016). Correlation between C-Peptide Level and Chronic Microvascular Complications in Type 2 Diabetes Mellitus Sudanese Patients. Open Access Library Journal, 3, e2634. doi: http://dx.doi.org/10.4236/oalib.1102634.

References

[1]  International Diabetes Federation (2011) IDF Diabetes Atlas. 5th Edition, International Diabetes Federation, Brussels.
[2]  Balla, S.A., Abdalla, A.A., Elmukashfi, T.A. and Ahmed, H.A. (2014) Hypertension among Rural Population in Four States: Sudan 2012. Global Journal of Health Science, 6, 206.
http://dx.doi.org/10.5539/gjhs.v6n3p206
[3]  Muninarayana, C., Balachandra, G., Hiremath, S., Iyengar, K. and Anil, N. (2010) Prevalence and Awareness Regarding Diabetes Mellitus in Rural Tamaka, Kolar. International Journal of Diabetes in Developing Countries, 30, 18.
http://dx.doi.org/10.4103/0973-3930.60005
[4]  Tesfaye, S. and Gill, G. (2011) Chronic Diabetes Complications in Africa. African Journal of Diabetes Medicine, 19.
[5]  Frank, R. (2004) Diabetic Retinopathy. New England Journal of Medicine, 350, 48-58.
http://dx.doi.org/10.1056/NEJMra021678
[6]  Mbanya, J.C. and Sobngwi, E. (2003) Diabetes in Africa. Diabetes Microvascular and Macrovascular Disease in Africa. Journal of Cardiovascular Risk, 2, 97-102.
http://dx.doi.org/10.1177/174182670301000204
[7]  Noubiap, J.J.N., Naidoo, J. and Kengne, A.P. (2015) Diabetic Nephropathy in Africa: A Systematic Review. World Journal of Diabetes, 6, 759-773.
http://dx.doi.org/10.4239/wjd.v6.i5.759
[8]  Kengne, A.P., Sobngwi, E., Echouffo-Tcheugui, J.B. and Mbanya, J.C. (2013) New Insights on Diabetes Mellitus and Obesity in Africa—Part 2: Prevention, Screening and Economic Burden. Heart, 99, 1072-1077.
http://dx.doi.org/10.1136/heartjnl-2013-303773
[9]  Mbanya, J.C., Motala, A.A., Sobngwi, E., Assah, F.K. and Enoru, S.T. (2010) Diabetes in Sub-Saharan Africa. Lancet, 375, 2254-2266.
http://dx.doi.org/10.1016/S0140-6736(10)60550-8
[10]  Fahal, I.H. (2009) The Diabetic Kidney—“A Systematic, Diabetes Renal Service, Better for Patients and Clinicians”. Sudan Medical Journal, 45.
[11]  Parving, H.-H. (1996) Initiation and Progression of Diabetic Nephropathy. New England Journal of Medicine, 335, 1682-1683.
http://dx.doi.org/10.1056/NEJM199611283352212
[12]  Andersen, A.R., Sandahl Christiansen, J., Andersen, J.K., Kreiner, S. and Deckert, T. (1983) Diabetic Nephropathy in Type-1 (Insulin-Dependent) Diabetes: An Epidemiological Study. Diabetologia, 25, 496-501.
http://dx.doi.org/10.1007/BF00284458
[13]  DeFronzo, R.A. (1995) Diabetic Nephropathy: Etiologic and Therapeutic Considerations. Diabetes Reviews, 3, 510- 564.
[14]  Razmaria, A.A. (2015) Diabetic Neuropathy. JAMA, 314, 2202.
http://dx.doi.org/10.1001/jama.2015.15899
[15]  Tesfaye, S., Stevens, L., Stephenson, J., et al., on Behalf of the EURODIAB IDDM Study Group (1996) The Prevalence of Diabetic Neuropathy and Its Relation to Glycaemic Control and Potential Risk Factors: The EURODIAB IDDM Complications Study. Diabetologia, 39, 1377-1384.
http://dx.doi.org/10.1007/s001250050586
[16]  Boulton, A.J., Malik, R.A., Arezzo, J.C. and Sosenko, J.M. (2004) Diabetic Somatic Neuropathies. Diabetes Care, 27, 1458-1486.
http://dx.doi.org/10.2337/diacare.27.6.1458
[17]  Dyck, P.J., Kratz, K.M., Karnes, J.L., et al. (1993) The Prevalence by Staged Severity of Various Types of Diabetic Neuropathy, Retinopathy, and Nephropathy in a Population-Based Cohort: The Rochester Diabetic Neuropathy Study. Neurology, 43, 817-824.
http://dx.doi.org/10.1212/WNL.43.4.817
[18]  Bos, M. and Agyemang, C. (2013) Prevalence and Complications of Diabetes Mellitus in Northern Africa, a Systematic Review. BMC Public Health, 13, 387.
http://dx.doi.org/10.1186/1471-2458-13-387
[19]  Palmer, J.P., Fleming, G.A., Greenbaum, C.J., et al. (2004) C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve Beta-Cell Function: Report of an ADA Workshop, 21-22 October 2001. Diabetes, 53, 250-264.
[20]  Marques, R.G., Fontaine, M.J. and Rogers, J. (2004) C-Peptide: Much More than a Byproduct of Insulin Biosynthesis. Pancreas, 29, 231-238.
http://dx.doi.org/10.1097/00006676-200410000-00009
[21]  Gross, J.L., de Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L. and Zelmanovitz, T. (2005) Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care, 28, 164-176.
[22]  Sari, R. and Balci, M.K. (2005) Relationship between C Peptide and Chronic Complications in Type-2 Diabetes Mellitus. Journal of the National Medical Association, 97, 1113-1118.
[23]  Lev-Ran, A., Hwang, D., Barseghian, G. and Hill, L.R. (1986) Control of Noninsulin Dependent Diabetes Is Not Correlated with Endogenous Insulin Secretion. Diabetes & Metabolism, 12, 325-328.
[24]  Johansson, J., Ekberg, K., Shafqat, J., et al. (2002) Molecular Effects of Proinsulin C-Peptide. Biochemical and Biophysical Research Communications, 295, 1035-1040.
http://dx.doi.org/10.1016/S0006-291X(02)00721-0
[25]  Hills, C.E., Brunskill, N.J. and Squires, P.E. (2010) C-Peptide as a Therapeutic Tool in Diabetic Nephropathy. American Journal of Nephrology, 31, 389-397.
http://dx.doi.org/10.1159/000289864
[26]  Mughal, R.S., Scragg, J.L., Lister, P., et al. (2010) Cellular Mechanisms by Which Proinsulin C-Peptide Prevents Insulin-Induced Neointima Formation in Human Saphenous Vein. Diabetologia, 53, 1761-1771.
http://dx.doi.org/10.1007/s00125-010-1736-6
[27]  Michaud, D.S., Wolpin, B., Giovannucci, E., Liu, S., Cochrane, B., Manson, J.E., Pollak, M.N., Ma, J. and Fuchs, C.S. (2007) Prediagnostic Plasma C-Peptide and Pancreatic Cancer Risk in Men and Women. Cancer Epidemiology, Biomarkers & Prevention, 16, 2101.
http://dx.doi.org/10.1158/1055-9965.EPI-07-0182
[28]  Ma, J., Giovannucci, E., Pollak, M., Leavitt, A., Tao, Y., Gaziano, J.M. and Stampfer, M.J. (2004) A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men. Journal of the National Cancer Institute, 96, 546-553.
http://dx.doi.org/10.1093/jnci/djh082
[29]  Patel, N., Taveira, T.H., Choudhary, G., Whitlatch, H. and Wu, W.-C. (2012) Fasting Serum C-Peptide Levels Predict Cardiovascular and Overall Death in Nondiabetic Adults. Journal of the American Heart Association, 1, e003152.
http://dx.doi.org/10.1161/jaha.112.003152
[30]  Elmahdi, E.M., Kaballo, A.M. and Mukhtar, E.A. (1991) Features of Non-Insulin-Dependent Diabetes Mellitus (NIDDM) in the Sudan. Diabetes Research and Clinical Practice, 11, 59-63.
http://dx.doi.org/10.1016/0168-8227(91)90142-Z
[31]  Mosier, M.A. (1984) Circulating C Peptide and Diabetic Retinopathy. Diabetes Research, 1, 151-154.
[32]  Suzuki, K., Watanabe, K., Motegi, T. and Kajinuma, H. (1989) High Prevalence of Proliferative Retinopathy in Diabetic Patients with Low Pancreatic B-Cell Capacity. Diabetes Research and Clinical Practice, 6, 45-52.
http://dx.doi.org/10.1016/0168-8227(89)90056-9
[33]  Inukai, T., Matsutoma, R., Tayama, K., Aso, Y. and Takemura, Y. (1999) Relation between the Serum Level of C Peptide and Risk Factors for Coronary Heart Disease and Diabetic Microangiopathy in Patients with Type-2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 107, 40-45.
http://dx.doi.org/10.1055/s-0029-1212071
[34]  Madsbad, S., Laurtzen, E., Faber, O.K. and Binder, C. (1986) The Effect of Residual Beta-Cell Function on the Development of Diabetic Retinopathy. Diabetic Medicine, 3, 42-45.
http://dx.doi.org/10.1111/j.1464-5491.1986.tb00704.x
[35]  Kim, B.-Y., Jung, C.-H., Mok, J.-O., Kang, S.-K. and Kim, C.-H. (2012) Association between Serum C-Peptide Levels and Chronic Microvascular Complications in Korean Type 2 Diabetic Patients. Acta Diabetologica, 49, 9-15.
http://dx.doi.org/10.1007/s00592-010-0249-6
[36]  Nilsson, P., Lundgren, H., Soderstrom, M., Fagerstrom, K.O. and Nilsson-Ehle, P. (1996) Effects of Smoking Cessation on Insulin and Cardiovascular Risk Factors—A Controlled Study of 4 Months’ Duration. Journal of Internal Medicine, 240, 189-194.
http://dx.doi.org/10.1046/j.1365-2796.1996.16844000.x

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413